Ph.D., pharmacology, University of North Carolina School of Medicine; B.A., psychology, and M.S., biology, Boston College
Summary of Experience
Dr. McGivney is a widely recognized expert in health care coverage policy and in drug and medical device regulatory policy. He regularly consults to pharmaceutical and biotech companies regarding the positioning of drugs, biologics, and devices in the marketplace. Dr. McGivney's work focuses on developing strategies for favorable coverage policies, positioning in clinical guidelines, and pricing, as well as determining the type, quality, and quantity of data necessary to achieve acceptance by clinicians. Further, he focuses on evolving financial (e.g., risk-sharing) and payment methods and the impact of same on the prescription and sale of drug/biologic products. Prior to his current role, Dr. McGivney served for 15 years as CEO of the National Comprehensive Cancer Network (NCCN), where he was responsible for developing strategies and programs to improve the quality of cancer care, including the NCCN Clinical Practice Guidelines in Oncology and the NCCN Drugs and Biologics Compendium, both of which are used extensively by payers to set coverage policy. Earlier in his career, Dr. McGivney held senior positions at Aetna Health Plans, where he directed several groups, including national coverage policy, technical assessment, clinical guidelines, and pharmacy policy; and at the American Medical Association, where he directed the division of health care technology and acted as liaison to the Food and Drug Administration. Dr. McGivney has authored or coauthored more than 50 abstracts and articles on a variety of health care matters, including the economics of health care, payments and coverage issues, clinical guidelines, and managed care, which have been published in journals such as Physician Executive, Journal of the National Comprehensive Cancer Network, American Journal of Managed Care, and Journal of American Medical Association. In addition, Dr. McGivney has delivered more than 100 presentations on a variety of health care topics, including the Affordable Care Act, outcomes data, coverage decisions, managed care, reimbursement and ethical issues involved in the introduction of new technology, and cost-effectiveness. He has served on numerous national boards and committees, including as president of the board of the Patient Advocate Foundation, and as a member of the Medicare Coverage Advisory Committee, and the United Network for Organ Sharing board of directors.
Anita J. Chawla